Galmed Pharmaceuticals (GLMD) Income from Continuing Operations (2013 - 2024)
Galmed Pharmaceuticals (GLMD) posted quarterly Income from Continuing Operations of 547000.0 for Q2 2024, up 15.64% year-over-year from 473000.0 in Q3 2023, and up 15.64% quarter-over-quarter from 473000.0 in Q2 2023.
Galmed Pharmaceuticals (GLMD) Income from Continuing Operations (2013 - 2024) Analysis & Trends
Galmed Pharmaceuticals' Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 547000.0 for Q2 2024.
- In Q2 2024, Income from Continuing Operations rose 15.64% year-over-year to 547000.0; the TTM figure through Jun 2024 stood at 1139000.0 (up 46.97% YoY), while the FY2025 annual figure was 316000.0, up 21.0% from the prior year.
- Income from Continuing Operations for Q2 2024 stood at 547000.0, up from 473000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 408000000.0 in Q3 2020, with the low at 408317000.0 in Q4 2020.
- The 5-year median for Income from Continuing Operations is 204000.0 (2021), against an average of 384300.0.
- Peak annual rise in Income from Continuing Operations reached 3709190.91% in 2020, while the deepest fall reached 32650.0% in 2020.
- Galmed Pharmaceuticals' Income from Continuing Operations stood at 408317000.0 in 2020, then jumped by 100.04% to 183000.0 in 2021, then slumped by 157.92% to 106000.0 in 2022, then jumped by 546.23% to 473000.0 in 2023, then increased by 15.64% to 547000.0 in 2024.
- Business Quant data shows GLMD's Income from Continuing Operations at 547000.0 in Q2 2024, 473000.0 in Q2 2023, and 106000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 547,000.00 |
| Jun 30, 2023 | 473,000.00 |
| Sep 30, 2022 | -106,000.00 |
| Jun 30, 2022 | 225,000.00 |
| Sep 30, 2021 | 183,000.00 |
| Mar 31, 2021 | 130,000.00 |
| Dec 31, 2020 | -408.32 Mn |
| Sep 30, 2020 | 408.00 Mn |
| Jun 30, 2020 | -5.24 Mn |
| Mar 31, 2020 | 262,000.00 |
| Dec 31, 2019 | 83.46 Mn |
| Sep 30, 2019 | -11,000.00 |
| Jun 30, 2019 | -16,000.00 |
| Mar 31, 2019 | -36,000.00 |
| Dec 31, 2018 | 3.71 Mn |
| Sep 30, 2018 | 809,000.00 |
| Jun 30, 2018 | -7,000.00 |
| Mar 31, 2018 | 29,000.00 |
| Dec 31, 2017 | 3.64 Mn |
| Sep 30, 2017 | 2.80 Mn |